A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk	hepatocellular carcinoma	Recruiting	Phase 4	2025-04-16		NCT06930573

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
The First Affiliated Hospital of Zhengzhou University	203

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	56

Clinical trials